BARBARA KAYIIRA: Open Payments
NPI 1659074110 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,434 in 183 payments from 19 companies in 2025. Trend: 2023 $120 · 2024 $4,528 · 2025 $5,434
Food & beverage: $5,434
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $721 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $676 |
| E.R. Squibb & Sons, L.L.C. | 14 | $543 |
| Corium, LLC | 13 | $472 |
| Janssen Pharmaceuticals, Inc | 13 | $418 |
| Indivior Inc. | 9 | $402 |
| Vanda Pharmaceuticals Inc. | 13 | $399 |
| Otsuka America Pharmaceutical, Inc. | 10 | $365 |
| Alkermes, Inc. | 11 | $360 |
| Lundbeck LLC | 10 | $223 |
Products named: VRAYLAR, CAPLYTA, REXULTI, COBENFY, Azstarys, SUBLOCADE, FANAPT, INVEGA SUSTENNA.
Industry payments across AZ — which companies pay providers there.
